Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsight
New York, USA, April 20, 2026 (GLOBE NEWSWIRE) -- Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsight
The pheochromocytoma and paraganglioma market is steadily evolving after years of dependence on surgery, symptom control, and a narrow range of systemic options like chemotherapy and radionuclide therapies. Newer treatment approaches, particularly radiopharmaceuticals such as 131I-MIBG and PRRT with 177Lu-DOTATATE, along with emerging radioligand strategies, are broadening the therapeutic landscape for advanced cases. At the same time, a growing pipeline of innovative radioligands, targeted agents, and combination regimens is advancing through clinical trials. This signals a gradual shift in the PCPG treatment paradigm toward more mechanism-driven and precision-focused therapies, mirroring trends observed in other rare oncology indications.
Recently published Pheochromocytoma and Paraganglioma Market Insights report includes a comprehensive understanding of current treatment practices, pheochromocytoma and paraganglioma emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Pheochromocytoma and Paraganglioma Market Summary
Discover which segment will drive growth in the PCPG market @ https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market
Key Factors Driving the Growth of the Pheochromocytoma and Paraganglioma Market
Aparna Thakur, Assistant Project Manager, Forecasting at DelveInsight, said that companies have a significant opportunity to enter the PCPG market due to the smaller number of approved targeted therapies.
Pheochromocytoma and Paraganglioma Market Analysis
Learn more about which PCPG therapies will dominate @ Pheochromocytoma and Paraganglioma Treatment Market
Pheochromocytoma and Paraganglioma Competitive Landscape
Some of the PCPG drugs under development include Lutetium [177Lu] oxodotreotide/dotatate (LUTATHERA) (Novartis), JZP3507 (ONC206) (Jazz Pharmaceuticals), [212Pb] VMT-α-Net (Perspective Therapeutics), HTL0039732 (Nxera Pharma), and others.
Novartis’ Lutetium (177Lu) oxodotreotide is a peptide receptor radionuclide therapy (PRRT) developed and commercialized by Novartis. It consists of the somatostatin analog dotatate labeled with the beta-emitting radioisotope lutetium-177, allowing precise delivery of ionizing radiation to tumor cells that express somatostatin receptors, particularly subtype 2. The therapy binds strongly to these receptor-positive cells and, once internalized, releases localized radiation that causes DNA damage and ultimately leads to tumor cell death.
As of January 2026, LUTATHERA’s orphan drug exclusivity in the United States has expired. However, its formulation patents, extending through 2039, including pediatric exclusivity, remain active and are currently under challenge by companies that have filed FDA applications referencing LUTATHERA. In the European Union, the primary patent protection is anticipated to expire in 2029.
Jazz Pharmaceuticals’ JZP3507 (previously known as ONC206) is an investigational oncology agent with a dual mechanism of action, functioning as a ClpP agonist and a dopamine D2 receptor (DRD2) antagonist. It is being assessed in early-phase clinical trials across multiple tumor types, including both central nervous system and non-CNS cancers such as pheochromocytoma and paraganglioma (PCPG), to address significant unmet needs in hard-to-treat malignancies.
Perspective Therapeutics’ VMT-α-NET is a clinical-stage targeted alpha therapy (TAT) radiopharmaceutical designed for the treatment and imaging of neuroendocrine tumors expressing somatostatin receptor subtype 2 (SSTR2), a rare and challenging cancer type. Perspective Therapeutics is also working with leading experts to further define the clinical potential of [212Pb] VMT-α-NET through investigator-initiated studies conducted both in the United States and internationally.
In October 2025, Perspective Therapeutics reported updated interim findings from its ongoing Phase I/II trial of [212Pb] VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors. The data, with a cutoff date of September 12, 2025, were presented at major scientific meetings, including the ESMO Congress 2025, the North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium, and the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
The anticipated launch of these emerging pheochromocytoma and paraganglioma therapies are poised to transform the pheochromocytoma and paraganglioma market landscape in the coming years. As these cutting-edge Pheochromocytomas and Paragangliomas therapies continue to mature and gain regulatory approval, they are expected to reshape the Pheochromocytomas and Paragangliomas market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about the latest drugs in the PCPG pipeline 2026, visit @ Pheochromocytoma and Paragangliomas Medication
Recent Developments in the Pheochromocytomas and Paragangliomas Market
What are Pheochromocytoma and Paraganglioma?
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors that arise from chromaffin cells of the body’s autonomic nervous system. Pheochromocytomas originate specifically in the adrenal medulla, whereas paragangliomas develop outside the adrenal glands along sympathetic and parasympathetic nerve chains, commonly in the head, neck, thorax, abdomen, or pelvis. These tumors can produce excess catecholamines, such as adrenaline and noradrenaline, leading to symptoms like hypertension, headaches, sweating, and palpitations, although some may be non-functional. While most PPGLs are benign, a subset can be malignant and metastasize. They are also notable for their strong genetic association, with a significant proportion linked to inherited syndromes involving mutations in genes such as SDHx, RET, and VHL.
Pheochromocytoma and Paraganglioma Epidemiology Segmentation
The pheochromocytoma and paraganglioma epidemiology section provides insights into the historical and current pheochromocytoma and paraganglioma patient pool and forecasted trends for the leading markets. PCPG’s actual diagnosed numbers are underestimated, as the disease is inactive and remains silent/asymptomatic for a long time. Considering that almost 50% of the cases are diagnosed after autopsy, the real patient burden is expected to be much higher.
The pheochromocytoma and paraganglioma market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:
Download the report to understand the unmet needs in PCPG treatment @ Pheochromocytoma and Paraganglioma Treatment Options
Scope of the Pheochromocytoma and Paraganglioma Market Report
Discover more about who is leading PCPG drug development @ Pheochromocytoma and Paraganglioma Clinical Trials
Table of Contents
Related Reports
Radioligand Therapies Market
Radioligand Therapies Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key RLT companies, including Novartis, Curium Pharma, Lantheus, Eli Lilly and Company, Fusion Pharmaceuticals, AstraZeneca, Clarity Pharmaceuticals, Bayer, ITM Isotope Technologies, ARTBIO, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutic, Nuclidium, and others.
PSMA-targeted Therapy Market
PSMA-targeted Therapy Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key PSMA-targeted therapy companies, including Lantheus, Telix Pharmaceuticals, Novartis, and others.
Prostate Cancer Market
Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key prostate cancer companies, including Sanofi, AstraZeneca, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Janssen Pharmaceutical, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, and others.
Neuroendocrine Tumors Market
Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key neuroendocrine tumors companies including Novartis, Merck, Pfizer, ITM Solucin GMBH, Camurus, Bristol Myers Squibb, Rayzebio, Exelixis, Ipsen, Takeda, Radiomedix, Orano Med, Perspective Therapeutics, Elicera Therapeutics, Chimerix, Enterome, Teclison, and others.
Gastroenteropancreatic Neuroendocrine Tumors Market
Gastroenteropancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GEP-NET companies including Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limite, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc, Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.